Cingulate gets FDA Complete Response Letter for CTx-1301
Cingulate said the FDA issued a Complete Response Letter for its CTx-1301 NDA on June 1, 2026, and the company is addressing CMC issues with plans to resubmit promptly. Management will present the commercialization and launch strategy for CTx-1301 at an upcoming event.